Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

4D Molecular Therapeutics (FDMT) Return on Capital Employed (2021 - 2025)

Historic Return on Capital Employed for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Q3 2025 value amounting to 0.56%.

  • 4D Molecular Therapeutics' Return on Capital Employed fell 2700.0% to 0.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.56%, marking a year-over-year decrease of 2700.0%. This contributed to the annual value of 0.45% for FY2024, which is 500.0% down from last year.
  • 4D Molecular Therapeutics' Return on Capital Employed amounted to 0.56% in Q3 2025, which was down 2700.0% from 0.48% recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Return on Capital Employed registered a high of 0.21% during Q2 2021, and its lowest value of 0.56% during Q3 2025.
  • Its 5-year average for Return on Capital Employed is 0.34%, with a median of 0.34% in 2024.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Return on Capital Employed skyrocketed by 2100bps in 2024, and later tumbled by -2700bps in 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Return on Capital Employed (Quarter) stood at 0.25% in 2021, then plummeted by -70bps to 0.43% in 2022, then grew by 21bps to 0.34% in 2023, then grew by 0bps to 0.34% in 2024, then plummeted by -65bps to 0.56% in 2025.
  • Its Return on Capital Employed was 0.56% in Q3 2025, compared to 0.48% in Q2 2025 and 0.4% in Q1 2025.